156 related articles for article (PubMed ID: 36683866)
41. Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects.
Feldman A; Wernly B; Strebinger G; Eder SK; Zandanell S; Niederseer D; Strasser M; Haufe H; Sotlar K; Paulweber B; Datz C; Aigner E
J Gastrointestin Liver Dis; 2021 Sep; 30(3):366-373. PubMed ID: 34375373
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
[TBL] [Abstract][Full Text] [Related]
43. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
[TBL] [Abstract][Full Text] [Related]
44. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
45. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease.
Vos B; Moreno C; Nagy N; Féry F; Cnop M; Vereerstraeten P; Devière J; Adler M
Acta Gastroenterol Belg; 2011 Sep; 74(3):389-94. PubMed ID: 22103042
[TBL] [Abstract][Full Text] [Related]
46. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.
Sookoian S; Pirola CJ
Aliment Pharmacol Ther; 2018 Jan; 47(1):16-25. PubMed ID: 29083036
[TBL] [Abstract][Full Text] [Related]
47. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
[TBL] [Abstract][Full Text] [Related]
48. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
Arora A; Sharma P
J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
[TBL] [Abstract][Full Text] [Related]
49. Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study.
Sumida Y; Toyoda H; Yasuda S; Kimoto S; Sakamoto K; Nakade Y; Ito K; Osonoi T; Yoneda M
J Atheroscler Thromb; 2024 May; ():. PubMed ID: 38777770
[TBL] [Abstract][Full Text] [Related]
50. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
Wong VW; Wong GL; Chan RS; Shu SS; Cheung BH; Li LS; Chim AM; Chan CK; Leung JK; Chu WC; Woo J; Chan HL
J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427
[TBL] [Abstract][Full Text] [Related]
51. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis.
Joshita S; Umemura T; Yamashita Y; Sugiura A; Yamazaki T; Fujimori N; Matsumoto A; Tanaka E
Hepatol Res; 2019 Oct; 49(10):1236-1243. PubMed ID: 31077509
[TBL] [Abstract][Full Text] [Related]
52. Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank.
Chahal D; Sharma D; Keshavarzi S; Arisar FAQ; Patel K; Xu W; Bhat M
Hepatol Int; 2022 Apr; 16(2):325-336. PubMed ID: 35178663
[TBL] [Abstract][Full Text] [Related]
53. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
54. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
Amernia B; Moosavy SH; Banookh F; Zoghi G
BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
[TBL] [Abstract][Full Text] [Related]
55. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
56. Whole-Exome Sequencing Identifies a Variant in Phosphatidylethanolamine N-Methyltransferase Gene to be Associated With Lean-Nonalcoholic Fatty Liver Disease.
Bale G; Vishnubhotla RV; Mitnala S; Sharma M; Padaki RN; Pawar SC; Duvvur RN
J Clin Exp Hepatol; 2019; 9(5):561-568. PubMed ID: 31695245
[TBL] [Abstract][Full Text] [Related]
57. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
[TBL] [Abstract][Full Text] [Related]
58. Hepatic microbiome in healthy lean and obese humans.
Suppli MP; Bagger JI; Lelouvier B; Broha A; Demant M; Kønig MJ; Strandberg C; Lund A; Vilsbøll T; Knop FK
JHEP Rep; 2021 Aug; 3(4):100299. PubMed ID: 34169247
[TBL] [Abstract][Full Text] [Related]
59. [The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD].
Honda A; Ishii I
Yakugaku Zasshi; 2022; 142(12):1335-1343. PubMed ID: 36450511
[TBL] [Abstract][Full Text] [Related]
60. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
Matsuba I; Matsuba R; Ishibashi S; Yamashita S; Arai H; Yokote K; Suganami H; Araki E
J Diabetes Investig; 2018 Nov; 9(6):1323-1332. PubMed ID: 29603684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
